Loading…
← CockpitCompetitor Analysis › CU6.AX Clarity Pharmaceuticals Ltd.Open in the cockpit ↗

Clarity Pharmaceuticals Ltd.CU6.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical Specialties
Momentum laggard 17
Mkt cap
$444M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$4.67M
20-day average traded
P/B
3.56×
price to book
ROE
-77.5%
delivered
Implied ROE
44.2%
what the price asks
Next earnings
106 days
4 Mar 2027
Close · AUDA$1.83
1D-3.2%
1W+10.2%
1M+2.2%
3M-30.1%
6M-33.2%
YTD-45.9%
1Y-51.3%
ATR %9.1%
52w lowhigh57.0% off high

What Clarity Pharmaceuticals does

No business profile yet.

Clarity Pharmaceuticals at a glance

Size Clarity Pharmaceuticals (CU6.AX) is an Australia Health Care company (Medical Specialties) with a market value of $444M, the 270th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.83 on 18 Nov 2026.

Performance Over six months the shares fell 33.2%, against -15.8% for the median peer and +1.2% for the Australia market (cap-weighted) — 4th lowest of 21 in its peer set.

Valuation It trades at 3.56× book value against a peer median of 2.58× (5th most expensive of 21).

Price implies The share price implies a return on equity of about 44.2%; Clarity Pharmaceuticals delivers -77.5%, so the price asks more than the business earns today.

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 86CU6.AX 68
Six months, rebased to 100: Clarity Pharmaceuticals against the median of its 20 peers (local-currency closes).

Clarity Pharmaceuticals financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$0A$0A$0A$0A$0
Revenue growth—————
Gross profit-A$283,530-A$283,530-A$185,083-A$153,068-A$100,513
EBITDA-A$119M-A$119M-A$78.4M-A$56.2M-A$36.1M
Net income-A$107M-A$107M-A$64.3M-A$42.3M-A$24.6M
Free cash flow-A$92.9M-A$92.9M-A$55.0M-A$43.7M-A$27.5M
Capital expenditureA$306,922A$306,922A$182,743A$504,005A$46,562
Total debtn/aA$0A$0A$0A$0

Quarterly statements and history in the cockpit →

Clarity Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%0%+20%300110688026603987002016MOBISI468530300289REG1V1763300515MDXG45493010976033099877ANGOCEVI300246301033CU6.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Clarity Pharmaceuticals is the large dot.

Fundamentals: return on equity against price-to-book

-75%-50%-25%0%20×40×300110688026603987002016MOBISI468530300289REG1V1763300515MDXG45493010979877ANGOCEVI301033CU6.AXReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Clarity Pharmaceuticals is the large dot.

Capital: ROE delivered against the ROE the price implies

-50%0%50%-50%0%50%300110688026603987002016SI468530300289300515MDXGANGOCU6.AXROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Clarity Pharmaceuticals is the large dot.

Clarity Pharmaceuticals competitors and peer comparison

How Clarity Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Clarity Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureCU6.AXPeer medianRank in peer set
1-month return+2.2%-6.4%6th highest of 21
6-month return-33.2%-15.8%4th lowest of 21
Return on equity-77.5%1.2%2nd lowest of 21
Price / book3.56×2.58×5th most expensive of 21
ROE the price implies44.2%16.0%2nd most demanding of 21
ROE delivered-77.5%1.2%lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/a-78%3.56×44.2%-77.5%
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%-44%3.39×16.6%-44.2%
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%2%2.33×22.1%2.0%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%8%1.04×9.2%7.9%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%2%0.61×4.7%1.8%
Mobia Medical MOBIUnited States$434M+2%+105%-246%2.75×12.8%n/a
Shoulder Innovations SIUnited States$432M+39%+55%-25%3.65×16.0%-25.1%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-68%26.75×70.0%-68.1%
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%-1%1.87×13.9%-0.5%
Revenio REG1V.HEFinland$428M-34%+44%9%1.74×11.5%9.1%
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%6%0.58×5.9%n/a
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%24%2.80×18.2%23.7%
MiMedx MDXGUnited States$464M-16%-23%-9%2.20×20.4%-8.5%
Eiken Chemical 4549.TJapan$466M-20%+4%4%1.68×10.5%4.2%
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%1%2.61×18.3%0.7%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%2%1.73×9.3%1.8%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-18%2.56×16.0%-18.3%
AngioDynamics ANGOUnited States$476M-4%+8%-19%2.93×13.4%-19.2%
CellaVision CEVI.STSweden$477M+64%+2%15%5.20×21.5%15.5%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-10%2.91×18.4%-10.2%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%16%3.71×18.3%15.8%

Questions

Which companies are Clarity Pharmaceuticals's closest peers?
The cockpit's peer set: Huaren Pharmaceutical (300110.SZ), Guangzhou Jet Bio-Filtration (688026.SS), Shanghai Kindly Enterprises Development (603987.SS), Guangdong Shirongzhaoye (002016.SZ), Mobia Medical (MOBI), Shoulder Innovations (SI), PROTEINA (468530.KS), Beijing Leadman Biochemistry (300289.SZ).
Is Clarity Pharmaceuticals expensive compared with its peers?
On price / book it trades at 3.56× against a peer median of 2.58×, 5th most expensive of 21 in its peer set. The share price implies a return on equity of about 44.2%; Clarity Pharmaceuticals delivers -77.5%, so the price asks more than the business earns today.
How has Clarity Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -33.2% against -15.8% for the median peer; over one year -51.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.